Shouyao Holdings Gets Ethics Approval for SY-5933 Phase Ib/II Study in KRAS G12C Mutated Tumors
Beijing-based Shouyao Holdings (Beijing) Co., Ltd (SHA: 688197) announced that it has received ethical approval...
Beijing-based Shouyao Holdings (Beijing) Co., Ltd (SHA: 688197) announced that it has received ethical approval...
Shanghai-listed biopharmaceutical company Shouyao Holdings (Beijing) Co., Ltd. (SHA: 688197) has announced plans to invest...
Beijing-based Shouyao Holdings (Beijing) Co., Ltd (SHA: 688197) has announced a strategic adjustment regarding its...
Shouyao Holdings (Beijing) Co., Ltd, a biopharmaceutical company headquartered in Beijing and listed on the...
Beijing-based Shouyao Holdings (Beijing) Co., Ltd (SHA: 688197) has announced that it has received ethical...
Beijing-based Shouyao Holdings (Beijing) Co., Ltd (SHA: 688197) has announced that it has received clinical...
Beijing-based Shouyao Holdings (Beijing) Co., Ltd (SHA: 688197) announced it has received ethical approval from...